Krsnaa Diagnostics Limited

rs,

S DO GOOD ... ® Date: 3i5t May, 2022 BSE Ltd. Corporate Service Department pt Floor, P.J. Towers, Dalal Street, Mumbai 400 001 Scrip ID: KRSNAA Scrip Code: 543328 Dear Sir/Madam, Subject: FY

rs 47

rvice Provider FY2022 and Q4 Performance 2 Strong Performance Across All Key Performance Indicators 47% Revenue CAGR 5Y (FY17-22) 101% PAT** CAGR 5Y (FY17-22) 46 Receivable Days 31st March, 2022 2,07

101%

rmance 2 Strong Performance Across All Key Performance Indicators 47% Revenue CAGR 5Y (FY17-22) 101% PAT** CAGR 5Y (FY17-22) 46 Receivable Days 31st March, 2022 2,071 Centres 23+ Mn Patients Served

Rs. 455

(FY17-22) 46 Receivable Days 31st March, 2022 2,071 Centres 23+ Mn Patients Served Last 5 Years Rs. 455 cr FY22 Revenue Rs. 133 cr | 29% FY22 EBITDA* Rs. 68 cr | 15% FY22 PAT Rs. 2.5 per share | 50% FY

Rs. 133

Days 31st March, 2022 2,071 Centres 23+ Mn Patients Served Last 5 Years Rs. 455 cr FY22 Revenue Rs. 133 cr | 29% FY22 EBITDA* Rs. 68 cr | 15% FY22 PAT Rs. 2.5 per share | 50% FY22 Final Dividend and Pay

29%

ch, 2022 2,071 Centres 23+ Mn Patients Served Last 5 Years Rs. 455 cr FY22 Revenue Rs. 133 cr | 29% FY22 EBITDA* Rs. 68 cr | 15% FY22 PAT Rs. 2.5 per share | 50% FY22 Final Dividend and Payout 14+

Rs. 68

ntres 23+ Mn Patients Served Last 5 Years Rs. 455 cr FY22 Revenue Rs. 133 cr | 29% FY22 EBITDA* Rs. 68 cr | 15% FY22 PAT Rs. 2.5 per share | 50% FY22 Final Dividend and Payout 14+ States 70+ Distric

15%

n Patients Served Last 5 Years Rs. 455 cr FY22 Revenue Rs. 133 cr | 29% FY22 EBITDA* Rs. 68 cr | 15% FY22 PAT Rs. 2.5 per share | 50% FY22 Final Dividend and Payout 14+ States 70+ Districts Locat

Rs. 2.5

ved Last 5 Years Rs. 455 cr FY22 Revenue Rs. 133 cr | 29% FY22 EBITDA* Rs. 68 cr | 15% FY22 PAT Rs. 2.5 per share | 50% FY22 Final Dividend and Payout 14+ States 70+ Districts Locations 17+ Mn No. of

50%

. 455 cr FY22 Revenue Rs. 133 cr | 29% FY22 EBITDA* Rs. 68 cr | 15% FY22 PAT Rs. 2.5 per share | 50% FY22 Final Dividend and Payout 14+ States 70+ Districts Locations 17+ Mn No. of Tests annuall

70%

Strong Revenue and Net Profit Growth Core Business Continues to Deliver Stellar Revenue Growth of 70% Y-o-Y Strong EBITDA of Rs. 133 Cr with margins of 29% and Net Profit of Rs. 68 Cr, up by 117% Y-o-Y

117%

wth of 70% Y-o-Y Strong EBITDA of Rs. 133 Cr with margins of 29% and Net Profit of Rs. 68 Cr, up by 117% Y-o-Y Total Revenue +15% YoY 4,555 3,965 Core Business Revenue Covid-19 Revenue Rs. Milli

“Maturity is on the basis of the project start date 3.”

“35 Krsnaa Diagnostics Edge One of the Fastest Growing Diagnostics Service Provider in the country Extensive Geographic Footprint Strong Brand Equity Scalable and Agile Business Model Disruptive Pricing Stakeholder Value Creation Total Centre count increased at a CAGR of 32% from 682 in FY18 to 2050+ in FY21 Centres across India with presence in 14 States.”

Notes

6

Regional Chains due to

1

Entry Limitations

1

Note

1

For further information please contact

1

Notes

* EBITDA is excluding CSR and ESOP expenses ** PAT without exceptional Items 3 FY2022: Strong Revenue and Net Profit Growth Core Business Continues to Deliver Stellar Revenue Growth of 70% Y-o-Y Strong EBITDA of Rs. 133 Cr with margins of 29% and Net Profit of Rs. 68 Cr, up by 117% Y-o-Y Total Revenue +15% YoY 4,555 3,965 Core Business Revenue Covid-19 Revenue Rs. Million +70% YoY 4,236 -78% YoY 2,491 1,474 FY21 FY22 FY21 FY22 FY21 EBITDA* +40% YoY 953 1,333 FY21 FY22

Notes

* EBITDA is excluding CSR and ESOP expenses ** PAT without exceptional Items 319 FY22 Revenue Mix COVID, 7% Profit After Tax** +117% YoY 684 315 FY21 Pathology, 38% Radiology, 47% FY22 Tele-Reporting, 8% 4 Q4 FY2022: Strong Net Profit Growth In Q4 FY22, Revenue up by 13% and Net Profit up by 21%. Performance driven by Core Business EBITDA was impacted due to investment in operationalizing new centres and increase in employee cost Core Business Revenue Covid-19 Revenue Rs. Million Total Revenue +13% YoY 1,082 +28% YoY 1,062 959 830 Q4FY21 Q4FY22 Q4FY21 Q4FY22 EBITDA* -16% YoY 338 284 Q4FY21 Q4FY22

Notes

* EBITDA is excluding CSR and ESOP expenses ** PAT without exceptional Items Profit After Tax** +21% YoY 148 179 Q4FY21 Q4FY22 Tele-Reporting, 10% Radiology, 50% 5 -84% YoY 129 Q4FY21 20 Q4FY22 Revenue Mix COVID, 2% Pathology, 38% Core Business Volumes Continues to Grow Tests In Million Total Number of Tests +92% YoY 4.78 2.49 +84% YoY 17.28 ▪ Higher awareness and visibility of Krsnaa diagnostics centres ▪ Strong tests volume growth visible in all modalities 9.38 ▪ High quality services at disruptive prices driving patient and tests count ▪ Addition of 20 Radiology, 103 Tele-reporting and 118 Pathology centres during the year Q4FY21 Q4FY22 FY21 FY22 Radiology Tests Tele-Reporting Tests Pathology Tests Covid-19 Tests +57% YoY 0.96 0.61 +40% YoY 2.45 3.42 0.22 0.25 0.91 1.06 +124% YoY 12.16 -18% YoY 0.74 0.90 5.42 3.42 1.21 0.15 0.05 Q4FY21 Q4FY22 FY21 FY22 Q4FY21 Q4FY22 FY21 FY22 Q4FY21 Q4FY22 FY21 FY22 Q4FY21 Q4FY22 FY21 FY22 6 Operational Performance Trend Strong Increase in Patient C

Notes

1. 2. 3. EBITDA is excluding CSR and ESOP expense EBIT including Other Income Profit After Tax is calculated without exceptional Items 13 Quarterly Financial Performance (Rs. Million) Core Business Covid-19 Business Revenue from Operations Other Income Total Income EBITDA1 Margin % EBIT2 Margin % Profit After Tax3 Margin % Reported Diluted EPS

Notes

1. 2. 3. EBITDA is excluding CSR and ESOP expense EBIT including Other Income Profit After Tax is calculated without exceptional Items Q4FY22 Q4FY21 Y-o-Y Growth Q3FY22 Q-o-Q Growth 1,062 20 1,082 41 1,123 284 26.2% 217 20.0% 179 16.6% 5.40 830 129 959 29 988 338 35.2% 263 27.5% 148 15.4% (9.53) 28.1% (84.5)% 12.9% 43.3% 13.7% (15.9)% (17.7)% 21.4% - 1,052 13 1,065 43 1,108 304 28.6% 237 22.3% 163 15.3% 5.64 1.0% - 1.7% (5.4)% 1.4% (6.7)% (8.6)% 10.1% (4.3)% 14 Balance Sheet Assets (In Million) FY21 FY22 Equity and Liabilities (In Million) FY21 FY22 Non-Current Assets Property, plant and equipment Capital work-in-progress Intangible assets Intangible asset under development Financial assets Investments Loans Other financial assets Deferred tax asset (net) Other non-current assets Current Assets Inventories Financial assets Trade receivables Cash and cash equivalents 3,563.91 5,420.06 3,072.80 3,833.79 37.18 12.28 - 2.90 - 282.57 23.15 - 2.91 - 159.51 1,155.15 0.00 7.88 279.24 114.61 2,

Regional Chains due to

▪ ▪ Krsnaa expertise and scale of business Access to high-cost radiology machines at relatively lower prices